• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内源性荧光抗癌药物。

Intrinsically Fluorescent Anti-Cancer Drugs.

作者信息

Kabir Md Lutful, Wang Feng, Clayton Andrew H A

机构信息

Optical Sciences Centre, Department of Physics and Astronomy, School of Science, Computing and Engineering Technologies, Swinburne University of Technology, Melbourne, VIC 3122, Australia.

Department of Chemistry and Biotechnology, School of Science, Computing and Engineering Technologies, Swinburne University of Technology, Melbourne, VIC 3122, Australia.

出版信息

Biology (Basel). 2022 Jul 28;11(8):1135. doi: 10.3390/biology11081135.

DOI:10.3390/biology11081135
PMID:36009762
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9405238/
Abstract

At present, about one-third of the total protein targets in the pharmaceutical research sector are kinase-based. While kinases have been attractive targets to combat many diseases, including cancer, selective kinase inhibition has been challenging, because of the high degree of structural homology in the active site where many kinase inhibitors bind. Despite efficacy as cancer drugs, kinase inhibitors can exhibit limited target specificity and rationalizing their target profiles in the context of precise molecular mechanisms or rearrangements is a major challenge for the field. Spectroscopic approaches such as infrared, Raman, NMR and fluorescence have the potential to provide significant insights into drug-target and drug-non-target interactions because of sensitivity to molecular environment. This review places a spotlight on the significance of fluorescence for extracting information related to structural properties, discovery of hidden conformers in solution and in target-bound state, binding properties (e.g., location of binding sites, hydrogen-bonding, hydrophobicity), kinetics as well as dynamics of kinase inhibitors. It is concluded that the information gleaned from an understanding of the intrinsic fluorescence from these classes of drugs may aid in the development of future drugs with improved side-effects and less disease resistance.

摘要

目前,制药研究领域中约三分之一的蛋白质靶点是基于激酶的。虽然激酶一直是对抗包括癌症在内的多种疾病的有吸引力的靶点,但由于许多激酶抑制剂结合的活性位点结构高度同源,选择性激酶抑制一直具有挑战性。尽管激酶抑制剂作为抗癌药物有效,但它们可能表现出有限的靶点特异性,并且在精确的分子机制或重排背景下合理化其靶点特征是该领域的一项重大挑战。红外、拉曼、核磁共振和荧光等光谱方法由于对分子环境敏感,有可能为药物-靶点和药物-非靶点相互作用提供重要见解。本综述重点关注荧光在提取与激酶抑制剂的结构性质、溶液中和靶点结合状态下隐藏构象的发现、结合性质(如结合位点的位置、氢键、疏水性)、动力学以及动态相关信息方面的重要性。得出的结论是,从对这类药物固有荧光的理解中收集到的信息可能有助于开发具有改善副作用和更低耐药性的未来药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/7843532b78e9/biology-11-01135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/b3a20369ece7/biology-11-01135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/3df5def472e7/biology-11-01135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/034b4d684332/biology-11-01135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/7843532b78e9/biology-11-01135-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/b3a20369ece7/biology-11-01135-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/3df5def472e7/biology-11-01135-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/034b4d684332/biology-11-01135-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07c1/9405238/7843532b78e9/biology-11-01135-g004.jpg

相似文献

1
Intrinsically Fluorescent Anti-Cancer Drugs.内源性荧光抗癌药物。
Biology (Basel). 2022 Jul 28;11(8):1135. doi: 10.3390/biology11081135.
2
Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).大分子拥挤现象:化学与物理邂逅生物学(瑞士阿斯科纳,2012年6月10日至14日)
Phys Biol. 2013 Aug;10(4):040301. doi: 10.1088/1478-3975/10/4/040301. Epub 2013 Aug 2.
3
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update.FDA 批准的小分子蛋白激酶抑制剂的特性:2020 年更新。
Pharmacol Res. 2020 Feb;152:104609. doi: 10.1016/j.phrs.2019.104609. Epub 2019 Dec 17.
4
Computational Approaches for the Design of (Mutant-)Selective Tyrosine Kinase Inhibitors: State-of-the-Art and Future Prospects.(突变体)选择性酪氨酸激酶抑制剂设计的计算方法:现状与未来展望
Curr Top Med Chem. 2020;20(17):1564-1575. doi: 10.2174/1568026620666200502005853.
5
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.BTK 活性位点抑制剂对全长 BTK 构象状态的差异化影响。
Elife. 2020 Nov 23;9:e60470. doi: 10.7554/eLife.60470.
6
Peptide inhibitors targeting protein kinases.靶向蛋白激酶的肽抑制剂。
Curr Pharm Des. 2009;15(21):2463-70. doi: 10.2174/138161209788682253.
7
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发:现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
8
Protein kinase inhibitors: contributions from structure to clinical compounds.蛋白激酶抑制剂:从结构到临床化合物的贡献
Q Rev Biophys. 2009 Feb;42(1):1-40. doi: 10.1017/S0033583508004745. Epub 2009 Mar 19.
9
Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.酪氨酸激酶组序列和结构空间中生物分子相互作用的计算蛋白质组学:解读激酶抑制剂选择性的分子基础。
Proteins. 2007 Mar 1;66(4):912-29. doi: 10.1002/prot.21287.
10
A historical overview of protein kinases and their targeted small molecule inhibitors.蛋白激酶及其靶向小分子抑制剂的历史概述。
Pharmacol Res. 2015 Oct;100:1-23. doi: 10.1016/j.phrs.2015.07.010. Epub 2015 Jul 21.

引用本文的文献

1
Development and Characterization of pFluor50, a Fluorogenic-Based Kinetic Assay System for High-Throughput Inhibition Screening and Characterization of Time-Dependent Inhibition and Inhibition Type for Six Human CYPs.pFluor50的开发与特性研究,一种基于荧光的动力学检测系统,用于高通量抑制筛选以及六种人细胞色素P450酶的时间依赖性抑制和抑制类型的表征。
Molecules. 2025 May 2;30(9):2032. doi: 10.3390/molecules30092032.
2
The Use of Tissue Concentrations of Biological and Small-Molecule Therapies in Clinical Studies of Inflammatory Bowel Diseases.生物和小分子疗法的组织浓度在炎症性肠病临床研究中的应用
Pharmaceutics. 2024 Nov 22;16(12):1497. doi: 10.3390/pharmaceutics16121497.
3

本文引用的文献

1
Fluorescent kinase inhibitors as probes in cancer.荧光激酶抑制剂作为癌症研究中的探针
Chem Soc Rev. 2021 Sep 7;50(17):9794-9816. doi: 10.1039/d1cs00017a. Epub 2021 Jul 22.
2
Red-Edge Excitation Shift Spectroscopy (REES): Application to Hidden Bound States of Ligands in Protein-Ligand Complexes.红边激发位移光谱(REES):在蛋白-配体复合物中配体隐藏结合态的应用。
Int J Mol Sci. 2021 Mar 4;22(5):2582. doi: 10.3390/ijms22052582.
3
Protein Binding of Lapatinib and Its N- and O-Dealkylated Metabolites Interrogated by Fluorescence, Ultrafast Spectroscopy and Molecular Dynamics Simulations.
Environmentally sensitive fluorescence of the topical retinoid adapalene.
局部用维甲酸类药物阿达帕林的环境敏感荧光。
Front Chem. 2024 Jul 8;12:1438751. doi: 10.3389/fchem.2024.1438751. eCollection 2024.
4
Insights into Halogen-Induced Changes in 4-Anilinoquinazoline EGFR Inhibitors: A Computational Spectroscopic Study.卤原子诱导 4-苯胺基喹唑啉型表皮生长因子受体抑制剂结构变化的理论研究。
Molecules. 2024 Jun 12;29(12):2800. doi: 10.3390/molecules29122800.
5
Innovative Approaches for Drug Discovery: Quantifying Drug Distribution and Response with Raman Imaging.药物发现的创新方法:利用拉曼成像量化药物分布与反应
Anal Chem. 2024 May 21;96(20):7926-7944. doi: 10.1021/acs.analchem.4c01413. Epub 2024 Apr 16.
6
Dual anticancer and antibacterial activity of fluorescent naphthoimidazolium salts.荧光萘并咪唑鎓盐的双重抗癌和抗菌活性
RSC Adv. 2023 Dec 14;13(51):36430-36438. doi: 10.1039/d3ra06555c. eCollection 2023 Dec 8.
7
Technologies for Direct Detection of Covalent Protein-Drug Adducts.直接检测共价蛋白质-药物加合物的技术
Pharmaceuticals (Basel). 2023 Apr 5;16(4):547. doi: 10.3390/ph16040547.
通过荧光、超快光谱和分子动力学模拟研究拉帕替尼及其N-和O-去烷基化代谢物的蛋白质结合。
Front Pharmacol. 2020 Oct 30;11:576495. doi: 10.3389/fphar.2020.576495. eCollection 2020.
4
Deducing the Conformational Properties of a Tyrosine Kinase Inhibitor in Solution by Optical Spectroscopy and Computational Chemistry.通过光谱学和计算化学推断溶液中酪氨酸激酶抑制剂的构象性质
Front Chem. 2020 Jul 28;8:596. doi: 10.3389/fchem.2020.00596. eCollection 2020.
5
Characterization of Locally Excited and Charge-Transfer States of the Anticancer Drug Lapatinib by Ultrafast Spectroscopy and Computational Studies.超快光谱和计算研究对抗癌药物拉帕替尼中局域激发和电荷转移态的特性描述。
Chemistry. 2020 Dec 4;26(68):15922-15930. doi: 10.1002/chem.202001336. Epub 2020 Oct 22.
6
Intracellular paired agent imaging enables improved evaluation of tyrosine kinase inhibitor target engagement.细胞内双试剂成像能够改进对酪氨酸激酶抑制剂靶点结合情况的评估。
Proc SPIE Int Soc Opt Eng. 2020 Feb;11219. Epub 2020 Feb 19.
7
Photobinding of Triflusal to Human Serum Albumin Investigated by Fluorescence, Proteomic Analysis, and Computational Studies.通过荧光、蛋白质组学分析和计算研究对曲氟尿苷与人血清白蛋白的光结合进行研究。
Front Pharmacol. 2019 Sep 20;10:1028. doi: 10.3389/fphar.2019.01028. eCollection 2019.
8
Assessment on the binding characteristics of dasatinib, a tyrosine kinase inhibitor to calf thymus DNA: insights from multi-spectroscopic methodologies and molecular docking as well as DFT calculation.评估达沙替尼(一种酪氨酸激酶抑制剂)与小牛胸腺 DNA 的结合特性:来自多光谱方法、分子对接和密度泛函理论计算的见解。
J Biomol Struct Dyn. 2020 Sep;38(14):4210-4220. doi: 10.1080/07391102.2019.1676824. Epub 2019 Oct 14.
9
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.4-氨基喹唑啉衍生物作为激酶抑制剂的最新进展及其在药物化学中的应用。
Eur J Med Chem. 2019 May 15;170:55-72. doi: 10.1016/j.ejmech.2019.03.004. Epub 2019 Mar 7.
10
An insight into the therapeutic potential of quinazoline derivatives as anticancer agents.喹唑啉衍生物作为抗癌剂的治疗潜力洞察。
Medchemcomm. 2017 Apr 7;8(5):871-885. doi: 10.1039/c7md00097a. eCollection 2017 May 1.